Few neutralizing antibodies for IGF have been developed, including xentuzumab (IgG1) and dusigitumab (IgG2)
I just mentioned a post-diagnosis weight gain of over 10% is associated with worse outcomes, so if that 5% weight loss can be combined with additional lifestyle factors, that gets towards attenuating that weight gain that patients may see and can be meaningful in terms of patients quality of life, how they tolerate their endocrine therapies, how they feel, and their body image
Each COA is traceable to a specific production lot and available on the Lab Tests page
The compound is one of the most-studied peptides in preclinical regenerative-research literature, with more than 100 published animal studies covering gastric and intestinal cytoprotection, tendon and ligament repair, angiogenic pathway activity, and central nervous system models
You have more control of the hunger, so patients can continue to make the right decision, Grieleber said